Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Introduction
Shattuck Labs, Inc. is a clinical-stage biotechnology company that is pioneering the development of dual-action fusion proteins, a new class of biologic medicines. Utilizing their proprietary Agonist Redirected Checkpoint (ARC®) platform, the company is dedicated to designing bi-functional fusion proteins capable of simultaneously inhibiting immune checkpoints and activating costimulatory pathways. This approach is instrumental in reactivating anti-tumor immune responses and modulating autoimmune mechanisms, addressing significant unmet needs in oncology and autoimmune disorders.
Innovative Technology and Platform
The core of Shattuck Labs’ innovation lies in its proprietary ARC® platform, which enables the rational design of fusion proteins with a dual mechanism of action. By targeting key immune checkpoints such as CD47 and PD-1 while concurrently stimulating costimulatory receptors like CD40 and OX40, the company is able to enhance the efficacy of immune-mediated treatments without the need for multiple separate therapies. This strategic integration of inhibitory and agonistic functions within a single molecule sets the company apart in the competitive biotechnology landscape.
Product Pipeline and Clinical Programs
Shattuck Labs is actively advancing several clinical programs with its innovative fusion protein candidates:
- SL-172154 (SIRPα-Fc-CD40L): Designed to block inhibitory checkpoints and stimulate immune activation, this candidate is undergoing early-phase clinical evaluation to address advanced cancer indications.
- SL-279252 (PD1-Fc-OX40L): Developed in collaboration with a major pharmaceutical partner, this compound exemplifies the company’s commitment to designing fusion proteins that combine checkpoint inhibition with costimulatory activation.
- Gamma Delta T Cell Engager Platform: Known as gadlen™, this innovative approach aims to bridge gamma delta T cells to tumor antigens, thereby enhancing the immune system’s ability to target and destroy cancer cells.
Throughout these programs, Shattuck Labs maintains a balanced focus on therapeutic innovation, clinical safety, and efficacy, which is thoroughly reflected in their robust preclinical data and ongoing Phase 1 clinical studies.
Market Position and Competitive Landscape
In the dynamic field of biotechnology, Shattuck Labs has carved out a unique niche by leveraging advanced protein engineering and novel therapeutic strategies. The company’s dual-action approach not only positions it as an innovator in the development of biologic medicines but also enables it to address complex diseases with limited treatment options. With clinical programs targeting both hematologic malignancies and autoimmune conditions, Shattuck Labs stands as a significant contributor in the realm of precision immunotherapy and therapeutic innovation.
Expertise, Experience, and Corporate Profile
With offices located in Austin, Texas and Durham, North Carolina, Shattuck Labs benefits from a strong foundation in regional biotech hubs known for their robust research and development ecosystems. The company’s leadership and scientific teams bring extensive expertise in protein engineering, immuno-oncology, and drug development. Their work not only reflects a deep understanding of molecular biology and immune regulation but also underscores a disciplined approach to clinical development that is critical for advancing novel therapeutics safely and effectively.
Understanding the Bi-Functional Fusion Protein Approach
At the heart of Shattuck Labs’ operations is the concept of a bi-functional fusion protein – a therapeutic designed to perform two critical functions within one molecule. This innovative approach allows for:
- Simultaneous inactivation of inhibitory checkpoints that normally prevent an effective immune response.
- Activation of costimulatory pathways that enhance the body's ability to combat cancer cells or manage autoimmune responses.
This dual mechanism is a testament to the company’s expertise in synthesizing complex biological data and leveraging cutting-edge protein design to create more potent therapies with a potentially improved safety profile.
Conclusion
Shattuck Labs, Inc. represents a forward-thinking force in the biotechnology industry. By integrating innovative dual-action fusion proteins with state-of-the-art research and a well-structured clinical development program, the company continues to bolster its position as an informed and experienced player in the field of biologic medicine. Investors and industry stakeholders will find that the company not only addresses pressing medical challenges but also exemplifies a commitment to scientific rigor and therapeutic innovation.
Shattuck Labs reported significant progress in clinical trials and announced key management changes. The Phase 1B trial of SL-172154 with mirvetuximab soravtansine in platinum-resistant ovarian cancer has begun enrollment. Initial data from this trial and others involving SL-172154 is expected in mid to late 2023. However, the company discontinued the SL-279252 program after failing to meet efficacy thresholds in Phase 1 trials. Financially, Shattuck reported a net loss of $25.4 million for Q4 2022, compared to a net income of $7.8 million a year prior, with R&D expenses rising to $82.9 million for the year. The company forecasts its cash reserves will sustain operations into H2 2024.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, will report its fourth quarter and full year 2022 financial results on February 23, 2023. The company specializes in bi-functional fusion proteins for cancer and autoimmune diseases, utilizing its proprietary Agonist Redirected Checkpoint (ARC®) platform. The lead program, SL-172154, is in multiple Phase 1 trials, aiming to block the CD47 checkpoint while activating the CD40 pathway. CEO Taylor Schreiber and other executives will present the results during a conference call at 4:45 p.m. ET, with a live webcast available for investors.
Shattuck Labs, Inc. (NASDAQ: STTK) has announced participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. The company specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Its lead program, SL-172154, is currently in multiple Phase 1 trials, targeting CD47 immune checkpoints while activating the CD40 pathway. Additionally, Shattuck is advancing its GADLEN™ platform, designed to connect gamma delta T cells with tumor antigens. The company is focused on transparent investor communication and compliance with regulatory obligations.
Shattuck Labs, Inc. (NASDAQ: STTK) provided a corporate update on January 9, 2023, emphasizing its focus on clinical execution for 2023. Key achievements in 2022 included the advancement of SL-172154 through various clinical trials for platinum-resistant ovarian cancer and its combination therapies. The company plans several critical data readouts in 2023, including results for SL-172154 in acute myeloid leukemia and higher-risk myelodysplastic syndromes. Shattuck ended Q3 2022 with approximately $185.1 million in cash, which is projected to sustain operations into the second half of 2024.
Shattuck Labs (NASDAQ: STTK) reported its Q3 2022 financial results and significant clinical advancements. The company completed enrollment in a Phase 1 trial for SL-172154 in platinum-resistant ovarian cancer, with complete data expected mid-2023. Additionally, the first patient was dosed in a combination trial with liposomal doxorubicin. Despite a cash position of $185.1 million, Shattuck incurred a net loss of $24.6 million for the quarter, increasing from $17.4 million YoY. The company anticipates its cash will fund operations into H2 2024.
Shattuck Labs, Inc. (NASDAQ: STTK) announced preclinical proof-of-concept data for its GADLEN platform at the 2022 SITC Annual Meeting. The data revealed two GADLEN candidates targeting CD20 and B7-H3, which enhanced the ability of γδT cells to kill tumor cells. These bispecific engagers showed a selective cytotoxic effect against B7-H3 expressing tumors and CD20 expressing lymphoma cells, indicating potential applications in treating various cancers. The platform's modularity allows for targeting specific tumor antigens, which could advance cancer therapies significantly.
Shattuck Labs (NASDAQ: STTK) announced its participation in three investor conferences in November and December 2022. CEO Dr. Taylor Schreiber will present at the Cowen’s 6th Annual IO Next Summit on November 11 and the Evercore ISI HealthCONx Conference on November 29. CFO Andrew Neill will present at the Piper Sandler Healthcare Conference on December 1. The company focuses on developing bi-functional fusion proteins to treat cancer and autoimmune diseases through its proprietary ARC® platform, which targets immune checkpoints and pathways simultaneously.
Shattuck Labs (NASDAQ: STTK) will report its Q3 2022 financial results on November 8, 2022, at 4:30 p.m. ET, during a conference call led by CEO Taylor Schreiber. Experts anticipate insights into the company's innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Currently, the SL-172154 and SL-279252 programs are in Phase 1 trials, utilizing Shattuck's proprietary ARC® platform. Investors can listen to the live webcast on Shattuck's website.
Shattuck Labs (NASDAQ: STTK) announced it will present a poster on its innovative bispecific Gamma Delta T Cell Engager (GADLEN) platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022, in Boston. The presentation, titled "Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity," will feature insights from Dr. Suresh de Silva and Dr. Derek Franklin. Shattuck is focused on developing novel biologic therapies for cancer and autoimmune diseases, leveraging its proprietary ARC® platform.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2022. The first event is Citi's 17th Annual BioPharma Conference on September 8, where CEO Taylor Schreiber will present at 2:40 p.m. ET. The second event is H.C. Wainwright's 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET. Both presentations will be available via live webcast on the company's website, with replays accessible for up to 90 days.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is the core focus of Shattuck Labs, Inc.?
How does the ARC® platform work?
Which therapeutic areas does Shattuck Labs target?
What distinguishes Shattuck Labs from other biotech companies?
Can you elaborate on the company’s product pipeline?
Does Shattuck Labs collaborate with other companies?
